Caspase-8 （CASPS） plays a key role in apoptosis. We examined by genotyping whether the -652 six-nucleotide insertion-deletion （6N ins/del） polymorphism in the CASP8 promoter region was associated with prostate can...Caspase-8 （CASPS） plays a key role in apoptosis. We examined by genotyping whether the -652 six-nucleotide insertion-deletion （6N ins/del） polymorphism in the CASP8 promoter region was associated with prostate cancer risk in a hospital-based case-control study of 406 Chinese prostate cancer patients and 408 age-matched cancerfree controls. Additionally, 23 prostate cancer tissues were analyzed for CASP8 mRNA expression. We found a significantly decreased prostate cancer risk for the 6N ins/del genotype [adjusted odds ratio （OR）=0.68; 95% confidence interval （C/）=0.51-0.92] and del/del genotype （OR=0.34; 95% CI=0.19-0.63） compared with the ins/ins genotype. The 6N del allele was associated dose-dependently with decreased prostate cancer risk （Ptrend = 0.001）. RT-PCR showed that individuals with the 6N del allele had lower CASP8 mRNA levels than those with the ins/ ins genotype （P = 0.024）. These findings suggested that the CASPS-652 6N ins/del polymorphism may affect the susceptibility to prostate cancer and reduce prostate cancer risk among Chinese men.展开更多
基金supported by National Natural Science Foundation of China (No. 30872084 and No. 30972444)the Key Programfor Basic Research of Jiangsu Provincial Department of Education (No.08KJA330001)"Qinglan Project" Foundation for the Young Academic Leader of Jiangsu Province (Zhengdong Zhang)
文摘Caspase-8 （CASPS） plays a key role in apoptosis. We examined by genotyping whether the -652 six-nucleotide insertion-deletion （6N ins/del） polymorphism in the CASP8 promoter region was associated with prostate cancer risk in a hospital-based case-control study of 406 Chinese prostate cancer patients and 408 age-matched cancerfree controls. Additionally, 23 prostate cancer tissues were analyzed for CASP8 mRNA expression. We found a significantly decreased prostate cancer risk for the 6N ins/del genotype [adjusted odds ratio （OR）=0.68; 95% confidence interval （C/）=0.51-0.92] and del/del genotype （OR=0.34; 95% CI=0.19-0.63） compared with the ins/ins genotype. The 6N del allele was associated dose-dependently with decreased prostate cancer risk （Ptrend = 0.001）. RT-PCR showed that individuals with the 6N del allele had lower CASP8 mRNA levels than those with the ins/ ins genotype （P = 0.024）. These findings suggested that the CASPS-652 6N ins/del polymorphism may affect the susceptibility to prostate cancer and reduce prostate cancer risk among Chinese men.
